A groundbreaking new study has found a notable connection between GLP-1 agonists—medications commonly prescribed for weight loss and diabetes management—and a decreased risk of breast cancer diagnosis. This discovery could signal a promising new strategy for breast cancer prevention.
The research analyzed data from more than 110,000 overweight and obese women aged 45 to 80. Results showed that those taking GLP-1 medications had approximately a 30% lower likelihood of developing breast cancer compared to those not on the drugs.
Researchers caution that this was an observational study, which means it cannot definitively prove that GLP-1 agonists directly reduce breast cancer risk. Nonetheless, similar findings in other studies strengthen the possibility of a beneficial role for these medications in cancer prevention.
READ MORE: Gloucester Rugby vs Newcastle Falcons LIVE: Gallagher Premiership Updates and Team News
READ MORE: Dramatic Cheltenham Crash Leaves Lorry Hanging Over Bridge
Elizabeth McDonald, a professor of radiology at Penn’s Perelman School of Medicine, highlighted the potential impact of this research: “GLP-1 medications, though not originally designed for cancer treatment, influence multiple pathways involved in cancer development. This makes them a compelling subject for further investigation in cancer prevention.”
The study was published in the JCO Oncology Practice journal.
Being overweight or obese is a well-known risk factor for breast cancer, and GLP-1 drugs help promote weight loss and improve metabolic health. Experts believe these effects might contribute to the reduced breast cancer risk observed.
Cancer Research UK reports that nearly 60,000 new breast cancer cases are diagnosed annually in the UK, with around 11,200 deaths each year. The charity notes that approximately 23% of breast cancer cases could be prevented by modifying lifestyle factors.
Other modifiable risks include smoking, alcohol consumption, and certain hormone-related treatments such as contraceptive pills and hormone replacement therapy, all of which can increase breast cancer risk.
This emerging evidence suggests that medications initially developed for weight management could play a new role in reducing breast cancer incidence—a development that researchers and patients alike are watching with great interest.